Teplizumab-mzwv
Brand names: Tzield · Active ingredient: Teplizumab
In short: TZIELD is indicated to : Delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 T1D. Delay the decline in endogenous insulin production in pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 T1D.
What is Teplizumab-mzwv used for?
TZIELD is indicated to :
Delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 T1D.
Delay the decline in endogenous insulin production in pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 T1D. This indication is approved under accelerated approval based on evidence of reduced C-peptide decline . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Limitations of Use:
There is limited evidence of safety and effectiveness in patients aged 45 years and older with Stage 2 T1D.
TZIELD is not effective as a disease modifying therapy in non-autoimmune dysglycemic conditions.
âš Boxed warning (FDA's strongest warning)
Serious, life-threatening cases of viral reactivation, including Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation have been reported with TZIELD. Patients who are immunocompromised are at increased risk. Serious cases have also been reported in adults with higher body surface area or comorbid conditions, such as adrenal insufficiency or cardiovascular disease. The majority of serious cases occurred in patients who continued TZIELD treatment despite persistent, severe lymphopenia. Severe lymphopenia may be prolonged in adults. (5.1, 5.4)
Test patients for active EBV and CMV infection prior to starting treatment. TZIELD is contraindicated in patients who are immunocompromised or have active viral infection (such as EBV or CMV infection). Adhere to lymphocyte count monitoring requirements and discontinuation recommendations. Monitor patients for signs and symptoms of viral reactivation following TZIELD treatment and for at least 2 months following the last infusion. If viral reactivation is suspected, discontinue TZIELD. (2.6, 4, 5.1, 5.4)
Teplizumab-mzwv dosage
Patients with Stage 2 T1D
Select adult and pediatric patients 1 year of age and older with Stage 2 T1D for TZIELD treatment to delay the onset of Stage 3 T1D based on the confirmation of:
At least two positive pancreatic islet cell autoantibodies, and
Dysglycemia without overt hyperglycemia using an oral glucose tolerance test (OGTT):
If an OGTT is not available, an alternative method for diagnosing dysglycemia without overt hyperglycemia may be appropriate.
In adults aged 18 years or older, recommend following the definition of dysglycemia used in clinical trials to diagnose dysglycemia prior to use of TZIELD due to the lack of specificity of other measures .
Ensure the patient's diagnosis confirms an autoimmune origin and does not suggest insulin resistance due to obesity, type 2 diabetes (T2D) or dysglycemia due to other forms of diabetes. These may include, but are not limited to, genetic forms of diabetes, maturity-onset diabetes of the young (MODY), latent autoimmune diabetes in adults (LADA), or diabetes secondary to medications or surgery.
Patients with Stage 3 T1D
Select pediatric patients aged 8 to 17 years recently diagnosed (within the last 8 weeks) with Stage 3 T1D for TZIELD treatment to delay the decline in endogenous insulin production based on confirmation of both of the following:
At least one positive pancreatic islet cell autoantibody
Peak C-peptide ≥0.2 pmol/mL on a mixed-meal tolerance test (if a mixed meal tolerance test is not available, an alternative method for measuring peak C-peptide ≥0.2 pmol/mL may be appropriate).
Prior to initiating TZIELD, obtain a complete blood count and liver enzyme tests. Use of TZIELD is not recommended in patients with the following conditions :
Lymphocyte count less than 1,000 lymphocytes/mcL
Hemoglobin less than 10 g/dL
Platelet count less than 150,000 platelets/mcL
Absolute neutrophil count less than 1,500 neutrophils/mcL
Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2 times the upper limit of normal (ULN) or bilirubin greater than 1.5 times ULN
Active serious infection or chronic active infection other than localized skin infections .
Prior to initiating treatment, evaluate patients for active EBV and CMV infection, including assessment of viral load [e.g., polymerase chain reaction (PCR) testing]. Consider expert consultation for appropriate laboratory and clinical evaluation to assess for active EBV or CMV infection. Use of TZIELD is contraindicated in patients who are immunocompromised or have active viral infection (such as EBV or CMV infection) .
Administer all age-appropriate vaccinations prior to starting TZIELD :
Administer live-attenuated (live) vaccines at least 8 weeks prior to TZIELD treatment. …
How to take Teplizumab-mzwv — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Viral Reactivation
Inform patients that TZIELD may cause serious, life-threatening viral reactivation, including EBV and CMV infections. Instruct patients to contact their healthcare provider immediately if they develop any symptoms of viral reactivation (such as fever, malaise, or swollen glands) during or at least 2 months after TZIELD treatment .
Cytokine Release Syndrome
Advise patients that TZIELD may cause cytokine release syndrome (CRS), which most commonly occurs during the first 5 days of treatment. Inform the patient that signs and symptoms of CRS may include fever, nausea, vomiting, fatigue, headache, muscle or joint pain, and increased transaminases or bilirubin. Instruct patients to contact their healthcare provider promptly if any of these symptoms occur. Inform patients that premedication will be given before each of the first 5 days of TZIELD infusion to help reduce the risk of CRS .
Serious Infections
Advise patients that TZIELD may lower the immune system's ability to fight infections. …
Warnings & precautions
Do not take this medicine if: TZIELD is contraindicated in patients who are immunocompromised or have active viral infection (such as EBV or CMV infection) .
Serious, life-threatening cases of viral reactivation, including EBV and CMV infections, have been reported with TZIELD. During and within 2 months of TZIELD treatment, if primary infection or reactivation of EBV or CMV occurs, it may present with increased severity, including EBV-associated lymphoproliferative disease and organ failure.
Patients who are immunocompromised, including patients with Down syndrome, may be at increased risk. TZIELD is contraindicated in patients who are immunocompromised or have active viral infection (such as EBV or CMV infection). The majority of serious viral reactivation cases occurred in patients who continued TZIELD despite persistent, severe lymphopenia. The duration of severe lymphopenia following TZIELD treatment may be prolonged in adults .
Serious cases have also been reported in adults with higher body surface area or comorbid conditions, such as adrenal insufficiency or cardiovascular disease.
Prior to initiating treatment with TZIELD, evaluate patients for active EBV and CMV infection and confirm absence of active infection on assessment of viral load (e.g., PCR). TZIELD is contraindicated in patients who are immunocompromised or have active viral infection (such as EBV or CMV infection) .
During treatment with TZIELD, regularly monitor lymphocyte counts and monitor patients for signs and symptoms of viral reactivation during treatment and for at least 2 months following the last infusion. If viral reactivation is suspected, discontinue TZIELD and obtain viral load (e.g., PCR) promptly. …
Teplizumab-mzwv side effects
The following serious adverse reactions are described elsewhere in the Prescribing Information:
Viral Reactivation
Cytokine Release Syndrome
Serious Infections
Lymphopenia
Hypersensitivity Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Placebo-Controlled Study in Adult and Pediatric Patients Aged 8 Years and Older with Stage 2 T1D (TN-10)
The data in Table 2 are derived from the placebo-controlled study (Study TN-10) in adult and pediatric patients aged 8 years and older with Stage 2 T1D . These data reflect exposure of 44 patients of whom 93% completed the full 14-day treatment course.
Table 2 presents common (≥5%) adverse reactions that occurred during treatment and through 28 days after the last study drug administration in patients with Stage 2 T1D in Study TN-10. Adverse reactions observed in pediatric patients 8 years and older who received TZIELD were consistent with those reported in adult patients in this study. …
About this medicine
Teplizumab-mzwv is a CD3-directed monoclonal antibody (humanized IgG1 kappa) that has a molecular weight of approximately 150 kilodalton (kDa) and is expressed from a recombinant Chinese hamster ovary (CHO) cell line.
TZIELD (teplizumab-mzwv) injection is supplied as a sterile, preservative-free, clear and colorless solution in a 2 mg/2 mL (1 mg/mL) single-dose vial for intravenous use. Each mL contains 1 mg of teplizumab-mzwv, dibasic sodium phosphate (0.26 mg), monobasic sodium phosphate (0.98 mg), polysorbate 80 (0.05 mg), sodium chloride (8.78 mg), and water for injection. The pH is 6.1.
How it works: Teplizumab-mzwv binds to CD3 (a cell surface antigen present on T lymphocytes) and delays the onset of Stage 3 T1D in adult and pediatric patients aged 1 year and older with Stage 2 T1D and delays the decline in endogenous insulin production in patients aged 8 to 17 years recently diagnosed with Stage 3 T1D. The mechanism may involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e8a39a5f-139c-4510-9777-71cbb00138fa. Read the full official label on DailyMed.
Related medicines
Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Insulin Lispro